Catalent 관리

관리 기준 확인 2/4

Catalent's CEO is Alessandro Maselli, appointed in Jul 2022, has a tenure of 2.25 years. total yearly compensation is $6.58M, comprised of 14% salary and 86% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth MX$53.44M. The average tenure of the management team and the board of directors is 2 years and 9.2 years respectively.

주요 정보

Alessandro Maselli

최고 경영자

US$6.6m

총 보상

CEO 급여 비율	14.0%
CEO 임기	2.3yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	9.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Alessandro Maselli 의 보수는 Catalent 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$1b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	n/a	n/a	-US$1b
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	US$7m	US$925k	-US$256m
Mar 31 2023	n/a	n/a	US$21m
Dec 31 2022	n/a	n/a	US$389m
Sep 30 2022	n/a	n/a	US$399m
Jun 30 2022	US$3m	US$654k	US$483m
Mar 31 2022	n/a	n/a	US$485m
Dec 31 2021	n/a	n/a	US$561m
Sep 30 2021	n/a	n/a	US$544m
Jun 30 2021	US$5m	US$640k	US$529m
Mar 31 2021	n/a	n/a	US$494m
Dec 31 2020	n/a	n/a	US$289m
Sep 30 2020	n/a	n/a	US$250m
Jun 30 2020	US$3m	US$483k	US$173m
Mar 31 2020	n/a	n/a	US$104m
Dec 31 2019	n/a	n/a	US$124m
Sep 30 2019	n/a	n/a	US$138m
Jun 30 2019	US$2m	US$450k	US$132m

보상 대 시장: Alessandro's total compensation ($USD6.58M) is about average for companies of similar size in the MX market ($USD5.84M).

보상과 수익: Alessandro's compensation has increased whilst the company is unprofitable.

CEO

Alessandro Maselli (52 yo)

2.3yrs

테뉴어

US$6,583,672

보상

Mr. Alessandro Maselli has been President of Catalent Pharma Solutions, Inc. from February 2019 and serves as its Director since July 01, 2022 and is its Chief Executive Officer and was its Chief Operation...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Greisch	Executive Chairman of the Board	6.7yrs	US$400.86k	0.028% MX$ 60.3m
Alessandro Maselli	President	2.3yrs	US$6.58m	0.025% MX$ 53.4m
Aristippos Gennadios	Group President of Pharma & Consumer Health Segment	5.8yrs	US$3.80m	0.063% MX$ 136.5m
Ricky Hopson	President	1.3yrs	US$972.31k	0.017% MX$ 36.0m
Matti Masanovich	Senior VP & CFO	1.3yrs	데이터 없음	0.0051% MX$ 11.2m
Michael Hatzfeld	VP & Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Charles Lickfold	Senior VP & Chief Information Officer	4.4yrs	데이터 없음	0.0060% MX$ 13.1m
Paul Surdez	Vice President of Investor Relations	4.8yrs	데이터 없음	데이터 없음
Joseph Ferraro	Senior VP	1.7yrs	데이터 없음	0.00061% MX$ 1.3m
Michael Grippo	Senior Vice President of Strategy & Corporate Development	5yrs	데이터 없음	0.013% MX$ 28.5m
Lisa Evoli	Senior VP & Chief Human Resources Officer	1.2yrs	데이터 없음	0.0030% MX$ 6.5m
Scott Gunther	Senior Vice President of Quality & Regulatory Affairs	7.4yrs	데이터 없음	0.022% MX$ 47.6m

2.0yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: CTLT *'s management team is not considered experienced ( 2 years average tenure), which suggests a new team.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Greisch	Executive Chairman of the Board	6.7yrs	US$400.86k	0.028% MX$ 60.3m
Alessandro Maselli	President	2.3yrs	US$6.58m	0.025% MX$ 53.4m
Donald Morel	Independent Director	8.9yrs	US$384.95k	0.026% MX$ 56.3m
Rolf Classon	Independent Director	10.2yrs	US$384.95k	0.0061% MX$ 13.3m
Daniel R. Marshak	Member of Advisory Board	9.2yrs	데이터 없음	데이터 없음
Jack Stahl	Independent Lead Director	10.2yrs	US$395.11k	0.015% MX$ 33.6m
Gregory Lucier	Independent Director	9.5yrs	US$387.61k	0.00077% MX$ 1.7m
J. Carroll	Independent Director	9.3yrs	US$426.36k	0.018% MX$ 38.6m
Edward Robinson	Member of Advisory Board	9.5yrs	데이터 없음	데이터 없음
Michael Buckley	Member of Advisory Board	9.2yrs	데이터 없음	데이터 없음
Carolyn Bertozzi	Member of Scientfic & Advisory Board	9.2yrs	데이터 없음	데이터 없음
Barry Buckland	Member of Advisory Board	9.2yrs	데이터 없음	데이터 없음

9.2yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: CTLT *'s board of directors are considered experienced (9.2 years average tenure).

Catalent 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

President recently sold Mex$1.6m worth of stock

Insufficient new directors

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold Mex$1.3m worth of stock

Investor sentiment deteriorates as stock falls 36%

Investor sentiment improves as stock rises 50%

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Danaher Reportedly Expresses Takeover Interest in Catalent

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Insider recently sold Mex$796k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold Mex$3.2m worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Now 22% undervalued

Investor sentiment deteriorated over the past week

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Investor sentiment deteriorated over the past week

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Executive Chair of the Board recently sold Mex$80m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Catalent, Inc. Announces Board Changes

Insider recently sold Mex$251k worth of stock

Insider recently sold Mex$251k worth of stock

Insufficient new directors

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022